Emergent BioSolutions (Emergent BioSolutions) EV-to-Revenue : 0.83 (As of Apr. 26, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Emergent BioSolutions's enterprise value is $850 Mil. Emergent BioSolutions's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,024 Mil. Therefore, Emergent BioSolutions's EV-to-Revenue for today is 0.83.

The historical rank and industry rank for Emergent BioSolutions's EV-to-Revenue or its related term are showing as below:

EBS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.81 Med: 3.63 Max: 6.64
Current: 0.83

During the past 13 years, the highest EV-to-Revenue of Emergent BioSolutions was 6.64. The lowest was 0.81. And the median was 3.63.

EBS's EV-to-Revenue is ranked better than
83.74% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs EBS: 0.83

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Emergent BioSolutions's stock price is $1.94. Emergent BioSolutions's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $19.97. Therefore, Emergent BioSolutions's PS Ratio for today is 0.10.

Emergent BioSolutions EV-to-Revenue Historical Data

The historical data trend for Emergent BioSolutions's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions EV-to-Revenue Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

3.49

3.43

1.52

1.26

0.85

Emergent BioSolutions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															1.26	1.59	1.15	0.88	0.85

Competitive Comparison of Emergent BioSolutions's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's EV-to-Revenue falls into.

Emergent BioSolutions EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Emergent BioSolutions's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	850.400	/	1023.8
	=	0.83

Emergent BioSolutions's current Enterprise Value is $850 Mil.
Emergent BioSolutions's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,024 Mil.

Emergent BioSolutions (NYSE:EBS) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Emergent BioSolutions's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.94	/	19.971
	=	0.10

Emergent BioSolutions's share price for today is $1.94.
Emergent BioSolutions's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.97.

Emergent BioSolutions EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (Emergent BioSolutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ER4:Germany ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Executives

Neal Franklin Fowler	director	C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
William Hartzel	officer: SVP, Bioservices	400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii	officer: Interim CEO	EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Paul Anthony Williams	officer: SVP, Products Business	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal	director	C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Glessner Coleen	officer: EVP, Quality & Ethics, and CPL	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox	officer: EVP, Ext Aff, GC, Corp Sec	400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl	officer: EVP, Chief Financial Officer	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey	officer: EVP, BioDefense Division	2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853
Robert Kramer	officer: Interim, EVP, BioSciences	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850